Brainsway (BWAY) director reports shares, RSUs and stock options
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Brainsway Ltd. director Mitrany Rayten Michal Ety filed an initial statement of beneficial ownership. The filing shows 12,500 Ordinary Shares held directly, including 6,250 shares and 6,250 RSUs that vest quarterly until March 5, 2028. It also reports stock options over 27,500 shares granted on January 13, 2020 expiring in 2028 with a NIS 15.26 exercise price, and options over 25,000 shares granted on March 5, 2024 expiring in 2034 with a NIS 11.17 exercise price, with 12,500 of those options vesting quarterly until March 5, 2028. The Ordinary Shares may be represented by American Depositary Shares on a one-for-one basis.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Mitrany Rayten Michal Ety
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Options (right to buy) | -- | -- | -- |
| holding | Stock Options (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Options (right to buy) — 27,500 shares (Direct);
Ordinary Shares — 12,500 shares (Direct)
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. This figure includes: (i) 6,250 ordinary shares, and (ii) unvested restricted stock units ("RSUs") to receive 6,250 ordinary shares that vest quarterly until March 5, 2028, with each RSU representing a contingent right to receive one ordinary share. Stock options were granted on January 13, 2020, and were fully vested by November 28, 2023. The exercise price is NIS 15.26 per share. Stock options were granted on March 5, 2024, with the remaining options to purchase 12,500 ordinary shares vesting in equal quarterly installments until March 5, 2028. The exercise price is NIS 11.17 per share.
FAQ
What does Brainsway (BWAY) director Mitrany Rayten Michal Ety report on this Form 3?
The Form 3 reports initial holdings of Brainsway securities, not new trades. It shows direct ownership of 12,500 Ordinary Shares plus stock options and RSUs that vest over time, establishing the director’s baseline position as of the reporting date.
What stock options held by the Brainsway (BWAY) director are disclosed?
The director holds options over 27,500 Ordinary Shares granted January 13, 2020, expiring in 2028 with a NIS 15.26 exercise price, and options over 25,000 shares granted March 5, 2024, expiring in 2034 with a NIS 11.17 exercise price, subject to vesting schedules.
What is the vesting schedule for the newer Brainsway (BWAY) stock options?
The March 5, 2024 grant includes remaining options to purchase 12,500 Ordinary Shares. These options vest in equal quarterly installments until March 5, 2028, spreading the director’s additional exercisable rights over a four-year period, as long as vesting conditions are met.
Are there any stock options already fully vested for the Brainsway (BWAY) director?
Yes. The stock options granted on January 13, 2020 are described as fully vested by November 28, 2023. This means the entire 27,500-share option grant is exercisable, subject to its NIS 15.26 exercise price and expiration date in 2028.